Puckrin R, Atenafu EG, Claudio JO, Chan S, Gupta V, Maze D, McNamara C, Murphy T, Shuh AC, Yee K, Sibai H, Minden MD, Wei C, Stockley T, Kamel-Reid S, Schimmer AD. Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. haematol [Internet]. 2021Jan.1 [cited 2024Nov.24];106(1):56-3. Available from: https://haematologica.org/article/view/9590